Phase 1 UC-MSC Stem Cell Trial, Primary Ovarian Insufficiency
ClinicalTrials.gov Studies
Summary
NIH registered a Phase 1 clinical trial (NCT07551895) evaluating umbilical cord mesenchymal stem cell (UC-MSC) injection (HS_SW01 cells) in patients with Primary Ovarian Insufficiency (POI). The trial aims to assess safety, tolerability, and efficacy of the investigational stem cell therapy. Participants will be enrolled after signing informed consent and meeting protocol inclusion/exclusion criteria.
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NIH registered a new Phase 1 clinical trial (NCT07551895) investigating human umbilical cord mesenchymal stem cell injection (HS_SW01 cells) for the treatment of Primary Ovarian Insufficiency (POI). The trial will evaluate safety, tolerability and efficacy endpoints in enrolled participants who meet inclusion/exclusion criteria and sign informed consent.
Healthcare providers and clinical investigators should note this represents early-stage cellular therapy research in reproductive endocrinology. Sponsors of similar stem cell programs for women's health indications may reference this trial's design for regulatory pathway considerations.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Primary Ovarian Insufficiency
Phase 1 NCT07551895 Kind: PHASE1 Apr 27, 2026
Abstract
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of human umbilical cord mesenchymal stem cell injection (HS_SW01 cells injection) in patients with Primary Ovarian Insufficiency (POI).
Participants will be required to sign the informed consent form and will only be assigned to the study and enrolled after undergoing a series of tests and meeting the inclusion and exclusion criteria of the protocol.
Conditions: Primary Ovarian Insufficiency (Poi)
Interventions: HSSW01 cells injection, HSSW01 cells injection, HS_SW01 cells injection
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.